29th week of 2011 patent applcation highlights part 43 |
Patent application number | Title | Published |
20110177936 | MATERIALS AND METHODS FOR IMMOBILIZATION OF CATALYSTS ON SURFACES AND FOR SELECTIVE ELECTROLESS METALLIZATION - A method of rendering a substrate catalytic to electroless metal deposition comprising the steps of: (a) depositing a ligating chemical agent on the substrate, which is capable of both binding to the substrate and ligating to an electroless plating catalyst; and (b) ligating the electroless plating catalyst to the ligating chemical agent,
| 2011-07-21 |
20110177937 | PLATINUM COMPLEX, MANUFACTURING METHOD THEREOF AND PLATINUM CATALYST CONSTRUCTED THEREBY - A manufacturing method of a platinum complex is mixing chloroplatinic acid and a chelating agent with a solvent, wherein [PtCl | 2011-07-21 |
20110177938 | PROCESS FOR THE CONTINUOUS PRODUCTION OF A CATALYST - The invention relates to a process for the continuous production of a catalyst comprising an alloy of a metal of the platinum group and at least a second metal as alloying metal selected from among the metals of the platinum group and the transition metals, in which a catalyst comprising the metal of the platinum group is mixed with at least one complex each comprising the alloying metal to give an alloy precursor and the alloy precursor is heated in a continuously operated furnace to produce the alloy. | 2011-07-21 |
20110177939 | EXHAUST GAS PURIFYING CATALYST - An exhaust gas purifying catalyst is constituted by: noble metal particles ( | 2011-07-21 |
20110177940 | MICROPOROUS CARBON AND METHOD FOR MAKING THE SAME - A substantially homogeneous composite for making a carbon material includes a carbon precursor and an activation agent that is soluble in a solution including the carbon precursor. An amount of the activation agent used is sufficient to form the carbon material having at least 90% of a total pore volume of the carbon material composed of micropores, and 10% or less of the total pore volume composed of mesopores and macropores. | 2011-07-21 |
20110177941 | THERMOSENSITIVE RECORDING MATERIAL AND IMAGE RECORDING METHOD - A thermosensitive recording material including: a support; an undercoat layer containing at least a water-soluble resin; a thermosensitive coloring layer containing a leuco dye and a developer; and a protective layer containing a water-soluble resin and a fluorescent whitening agent, wherein the undercoat layer, the thermosensitive coloring layer, and the protective layer are formed in this order over the support, wherein the undercoat layer has a single layer structure or a multilayer structure, and the protective layer has a single layer structure or a multilayer structure, and wherein the undercoat layer has an air permeance of 150 mL/min or less. | 2011-07-21 |
20110177942 | HEAT-SENSITIVE RECORDING BODY AND METHOD FOR PRODUCING SAME - The present invention relates to a heat-sensitive recording material comprising one or more heat-sensitive recording layers, an intermediate layer and a protective layer that are formed on one side of a transparent support, and the present inventions provide a heat-sensitive recording material and a process for providing the heat-sensitive recording material, wherein the one or more heat-sensitive recording layers are formed from one or more heat-sensitive recording layer coating compositions that each contain a leuco dye and a developer, the intermediate layer is formed from an intermediate layer coating composition that contains a hydrazine-based compound and an oxazoline group-containing compound, and the protective layer is formed from a protective layer coating composition that contains a modified polyvinyl alcohol. | 2011-07-21 |
20110177943 | Benzyl-Substituted Thiadiazolyloxyphenylamidinium Salts - The present invention relates to benzyl-substituted thiadiazolyloxyphenylamidinium salts of the general formula (I), to a process for their preparation, to the use of the amidinium salts according to the invention for controlling unwanted microorganisms and to a composition for this purpose which comprises the thiadiazolyloxyphenylamidinium salts according to the invention. The invention furthermore relates to a method for controlling unwanted microorganisms by appying the compounds according to the invention to the microorganisms and/or their habitat. | 2011-07-21 |
20110177944 | Synergistic Fungicidal Mixtures - The present invention relates to a composition, comprising a 5-amino-3-oxo-2,3-dihydro-pyrazole of the formula I as defined in the claims and the description and at least one active compound II selected from groups A) to I) in a synergistically effective amount. | 2011-07-21 |
20110177945 | Composition comprising a pesticide and an alkoxylate of 2-propylheptylamine - The present invention relates to a composition comprising a pesticide and an alkoxylate. Moreover, the invention relates to the alkoxylate, to a process for its preparation and to its use as adjuvant in pesticide-comprising spray mixtures. The invention furthermore relates to a method of controlling phytopathogenic fungi and/or undesired vegetation and/or undesired insect or mite attack and/or for regulating the growth of plants, wherein the composition is allowed to act on the respective pests, their environment or the plants to be protected from the respective pest, on the soil and/or on undesirable plants and/or the crop plants and/or their environment. Furthermore, the invention relates to seed comprising the composition. | 2011-07-21 |
20110177946 | HERBICIDE COMBINATION COMPRISING DIMETHOXYTRIAZINYL-SUBSTITUTED DIFLUOROMETHANESULFONYLANILIDES - The present invention relates to a herbicide combination comprising components (A) and (B) where
| 2011-07-21 |
20110177947 | Use of Acylcyclohexanedione Carboxylic Acid or Salts Thereof in Combination with Acylcyclohexanedione Carboxylic Acid Esters for Improving the Development of Gramineous Plants - The present invention relates to the use of a combination of acylcyclohexanedione-carboxylic acids or salts thereof and acylcyclohexanedionecarboxylic esters for improving the development of gramineae. The invention also relates to a method for improving the development of gramineae, in which the plants or plant parts thereof are treated with this combination. | 2011-07-21 |
20110177948 | THICKENER FOR PLANT-COMPATIBLE CONCENTRATES THAT CAN BE DISPERSED IN WATER - The present invention relates to novel water-dispersed agrochemical formulations, for example water-based suspension concentrates, of active agrochemical ingredients, comprising a penetrant and a thickener from the class of the anionic polysaccharides which contains, as the repetitive base unit in the main chain, four sugar molecules (glucose, glucuronic acid, glucose, rhamnose), to a process for producing these formulations and to the use thereof for application of the active ingredients present. | 2011-07-21 |
20110177949 | Composition for Improving the Efficacy of Herbicides - The present invention relates to a novel composition for improving the effectiveness of herbicides, to the use of this composition for improving the effectiveness of herbicides, to a herbicidal agent which comprises this composition and at least one herbicide, and to the use of this herbicidal agent for controlling undesired plant growth. The composition comprises:
| 2011-07-21 |
20110177950 | Imidazole and Triazole Compounds, Their Use and Agents Containing the Same - The present invention relates to compounds of the formula I | 2011-07-21 |
20110177951 | MICROCAPSULES COMPRISING ACTIVE INGREDIENTS AND A METAL OXIDE SHELL, A METHOD FOR THEIR PREPARATION AND USES THEREOF - The present invention provides a process for preparing microcapsules comprising a core material encapsulated by a metal oxide shell, microcapsules obtained therewith and uses thereof. | 2011-07-21 |
20110177952 | TEMPLATE FOR A SUPERCONDUCTING COIL - A method is disclosed for making a template for a superconducting coil on a former ( | 2011-07-21 |
20110177953 | SUPERCONDUCTING FAULT CURRENT-LIMITER WITH VARIABLE SHUNT IMPEDANCE - A superconducting fault current-limiter is provided, including a superconducting element configured to resistively or inductively limit a fault current, and one or more variable-impedance shunts electrically coupled in parallel with the superconducting element. The variable-impedance shunt(s) is configured to present a first impedance during a superconducting state of the superconducting element and a second impedance during a normal resistive state of the superconducting element. The superconducting element transitions from the superconducting state to the normal resistive state responsive to the fault current, and responsive thereto, the variable-impedance shunt(s) transitions from the first to the second impedance. The second impedance of the variable-impedance shunt(s) is a lower impedance than the first impedance, which facilitates current flow through the variable-impedance shunt(s) during a recovery transition of the superconducting element from the normal resistive state to the superconducting state, and thus, facilitates recovery of the superconducting element under load. | 2011-07-21 |
20110177954 | SUPERCONDUCTING ELECTRICITY TRANSMISSION SYSTEM - The present disclosure generally relates to a superconducting power grid having one or more AC/DC converters. The superconducting grid may further include one or more pairs of superconducting DC cables connecting each AC/DC converter. Each pair of superconducting DC cables may include a first positive polarity cable and a first negative polarity cable. The grid may also include at least one switching device configured to operatively connect at least one of the first and second AC/DC converters with at least one of the pairs of superconducting DC cables, the switching device further configured to adjust the polarity of at least one of the polarity cables. Other embodiments and implementations are also within the scope of the present disclosure. | 2011-07-21 |
20110177955 | MULTIPLEXED PROTEIN ADSORPTION ASSAY - A multiplexed assay method capable of measuring the interaction of one or more protein, polypeptide or peptide solutions with one or more substrate surfaces comprises contacting each of the wells of a multiwell substrate with the same or different protein solution, the surfaces of said wells being the same as that of said substrate or being substrate surface treated and/or coated to provide test surfaces, and determining the level of protein adsorption in each of said wells. | 2011-07-21 |
20110177956 | METHOD AND SYSTEM OF PREDICTING CLINICAL OUTCOME FOR A PATIENT WITH CONGESTIVE HEART FAILURE - A method of predicting a clinical outcome for a patient with congestive heart failure is disclosed. A plurality of nonlinear first PCI models are identified based on a biomarker dataset, each of the models having a number of distinct terms. One or more second PCI models are identified based on the biomarker dataset, each of these models having a number of distinct terms which corresponds to the number of distinct terms for one or more of the nonlinear first PCI models. Each of the plurality of nonlinear first PCI models are statistically compared to one of the one or more second PCI models having a corresponding number of distinct terms to determine a preference for higher versus lower degree of nonlinearity or preference for shorter versus longer memory length. The clinical outcome is predicted based on the preference for higher versus lower degree of nonlinearity or memory length preference. | 2011-07-21 |
20110177957 | Polymorphisms Associated With Age-Related Macular Degeneration And Methods For Evaluating Patient Risk - The present invention provides for certain polynucleotide sequences that have been correlated to AMD. These polynucleotides are useful as diagnostics, and are preferably used to fabricate an array, useful for screening patient samples. The array is used as part of a laboratory information management system, to store and process additional patient information in addition to the patient's genomic profile. As described herein, the system provides an assessment of the patient's risk for developing AMD, risk for disease progression, and the likelihood of disease prevention based on patient controllable factors. | 2011-07-21 |
20110177958 | METHODS AND MATERIALS FOR IDENTIFYING POLYMORPHIC VARIANTS, DIAGNOSING SUSCEPTIBILITIES, AND TREATING DISEASE - The invention is directed to materials and methods associated with polymorphic variants in two enzymes involved in folate-dependent and one-carbon metabolic pathways: MTHFD1 (5,10-methylenetetrahydrofolate dehydrogenase, 5,10-methenyltetrahydrofolate cyclohydrolase, 10-formyltetrahydrofolate synthetase) and methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like (MTHFD1L). Diagnostic and therapeutic methods are provided involving the correlation of polymorphic variants in MTHFD1, MTHFD1, and other genes with relative susceptibility for various pregnancy-related and other complications. | 2011-07-21 |
20110177959 | Methods and Devices for Detecting Kidney Transplant Rejection - Methods and devices for diagnosing, monitoring, or determining kidney transplant rejection or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining kidney transplant rejection or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | 2011-07-21 |
20110177960 | Microarray for monitoring gene expression in multiple strains of Streptococcus pneumoniae - The present invention features an array capable of monitoring gene expression patterns of multiple strains of | 2011-07-21 |
20110177961 | Method of Diagnosing Active Mycobacterium Tuberculosis with Detecting Chip - The present disclosure diagnoses mycobacterium tuberculosis, not mycobacterium tuberculosis complex only. Specific target genes are selected from regions of difference of mycobacterium tuberculosis. After hybridization with labeling substances, sputum samples are processed through color developments separately for obtaining images to be analyzed automatically. Thus, the present disclosure rapidly diagnoses mycobacterium tuberculosis in the sputum samples with a simple operation and a low cost. | 2011-07-21 |
20110177962 | SUCCESSIVE SAMPLING DEVICE AND ASSOCIATED METHOD - A method of determining a number of a solution constituent includes introducing a first number of solution constituents to a first test location, establishing a first binding environment for the introduced first number of solution constituents, creating a first residual number of solution constituents by binding a first plurality of solution constituents, establishing a second binding environment for the first residual number of solution constituents, creating a second residual number of solution constituents by binding a second plurality of solution constituents from the first residual number of solution constituents, obtaining a first signal associated with the bound first plurality of solution constituents, obtaining a second signal associated with the bound second plurality of solution constituents, and determining a second number of a constituent of interest based upon the obtained first signal and the obtained second signal. | 2011-07-21 |
20110177963 | Variation in the CHI3L1 Gene Influences Serum YKL-40 Levels, Asthma Risk and Lung Function - The present invention is based on the discovery that a single nucleotide polymorphism (SNP) present the chitinase 3-like 1 gene (CHI3L1) encoding YKL-40 or a regulatory domain of the CHI3L1 gene, is associated with elevated YKL-40 levels, as well as an increased risk for developing a lung disorder, including asthma, bronchial hyperresponsivity, and/or reduced lung function. | 2011-07-21 |
20110177964 | CHEMOSENSORY ARRAYS - A chemosensor array, a method of detecting ligands in a chemical mixture and a chemosensor system are provided. Chemosensor array designs are also provided. | 2011-07-21 |
20110177965 | COMPOSITIONS AND METHODS FOR PROGNOSIS OF GASTRIC CANCER - Described herein are compositions and methods for survival prediction in gastric cancer patients after surgical operation. The compositions are microRNA molecules associated with the prognosis of gastric cancer, as well as various nucleic acid molecules relating thereto or derived therefrom. | 2011-07-21 |
20110177966 | METHOD FOR PREDICTING THE RESPONSE TO A TREATMENT WITH ANAKINRA - The invention relates to a method for predicting the response of a patient to a treatment with anakinra, said method comprising a step of measuring the expression level of 7 genes in a biological sample of said patient, wherein said genes are GT-F2F2, CCT3, CROT, HNRPA3, ARL15, TMED5, and NRG3. | 2011-07-21 |
20110177967 | METHODS AND COMPOSITIONS USING SPLICING REGULATORY PROTEINS INVOLVED IN TUMOR SUPPRESSION - Methods and compositions for diagnosis and prognosis of mammalian carcinoma or cancer derived from primary epithelial cells and tissue fibrosis are designed using newly identified epithelial cell-type specific splicing factors ESRP1 and ESRP2, which have roles in tumor suppression. Diagnostic reagents for the detection of these splicing factors in nucleotide or protein form are useful in such methods. Therapeutic compositions can provide epithelial cells with these factors to maintain FGFR2 and assist in suppressing metastasis. A high throughput splicing assay to identify compounds that change splicing events is described. RNCP1 is also identified as a splicing factor and a diagnostic for conditions characterized by inappropriate FGFR2-splicing. | 2011-07-21 |
20110177968 | MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER USING MIR-17-3P - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer. The invention also provides methods of identifying anti-lung cancer agents. | 2011-07-21 |
20110177969 | THE ROLE OF IL17RD AND THE IL23-1L17 PATHWAY IN CROHN'S DISEASE - The present invention relates to methods of diagnosing susceptibility to Crohn's Diseaese by determining the presence or absence of susceptibility variants at the IL17RD locus. in one embodiment, the present invention provides a method of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4, where the presence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4 is indicative of susceptibility to Crohn's Disease. | 2011-07-21 |
20110177970 | METHODS FOR PREDICTING OR MONITORING WHETHER A PATIENT AFFECTED BY A CANCER IS RESPONSIVE TO A TREATMENT WITH A MOLECULE OF THE TAXOID FAMILY - The present invention concerns in vitro methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family based on a resistance expression signature, kits for performing the methods, and methods for screening or identifying a compound suitable for improving the treatment of a cancer with a molecule of the taxoid family or for reducing the resistance development during the treatment of a cancer with the molecule of the taxoid family. | 2011-07-21 |
20110177971 | METHOD FOR DIAGNOSING THE STAGE OF A THYROID TUMOR - The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer. | 2011-07-21 |
20110177972 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 2011-07-21 |
20110177973 | COMBINATORIAL SYNTHESIS AND USE OF LIBRARIES OF SHORT EXPRESSED NUCLEIC ACID SEQUENCES FOR THE ANALYSIS OF CELLULAR EVENTS - The present invention is concerned with the provision of screening assays. More specifically it relates to a method to a method for determining whether an exogenous stimulus is capable of eliciting at least one biological response in a host cell comprising the steps of (i) applying the said stimulus to a host cell which comprises a plurality of different polynucleotide constructs each construct comprising a unique expressed tag (EXT) operatively linked to an expression control sequence whose activity can be exclusively modulated by one specific signalling pathway or cellular sensor implemented in said host cell, said signalling pathway or cellular sensor being involved in eliciting a biological response and being sensitive for the exogenous stimulus, (i) determining the amount of at least one expressed tag; and (iii) comparing the amount of the at least one unique expressed tag to a suitable reference amount, whereby it is determined whether the exogenous stimulus is capable of eliciting at least one biological response in the host cell. | 2011-07-21 |
20110177974 | NEURAL PROTEINS AS BIOMARKERS FOR NERVOUS SYSTEM INJURY AND OTHER NEURAL DISORDERS - The present invention identities biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury. | 2011-07-21 |
20110177975 | DETECTION OF NUCLEIC ACID SEQUENCE DIFFERENCES USING THE LIGASE DETECTION REACTION WITH ADDRESSABLE ARRAYS - The present invention describes a method for identifying one or more of a plurality of sequences differing by one or more single base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences. The method includes a ligation phase, a capture phase, and a detection phase. The ligation phase utilizes a ligation detection reaction between one oligonucleotide probe, which has a target sequence-specific portion and an addressable array-specific portion, and a second oligonucleotide probe, having a target sequence-specific portion and a detectable label. After the ligation phase, the capture phase is carried out by hybridizing the ligated oligonucleotide probes to a solid support with an array of immobilized capture oligonucleotides at least some of which are complementary to the addressable array-specific portion. Following completion of the capture phase, a detection phase is carried out to detect the labels of ligated oligonucleotide probes hybridized to the solid support. | 2011-07-21 |
20110177976 | METHODS FOR PROMOTING WEIGHT LOSS AND ASSOCIATED ARRAYS - Methods of modulating body fat or weight loss are presented Nucleic acid and protein microarrays that comprise biomolecules associated with an obese host microbiome or a lean host microbiome are utilized for analysis. | 2011-07-21 |
20110177977 | ANTIBODIES FOR DETECTING OR MONITORING A MALIGNANT PLASMA CELL DISEASE - The present invention is directed to antibodies having specificity for a heavy chain class at the same time as having specificity for a first light chain. Such antibodies can be used in a method of detecting or monitoring a malignant plasma cell disease comprising determining in a sample the ratio between the relative amounts of immunoglobulins having:
| 2011-07-21 |
20110177978 | Apparatus and Method for Forming Self-Assembly Arrays - Apparatus and methods for forming self-assembly arrays of substances, such as nanoparticles, on a substrate are disclosed. The apparatus may include a substrate supporting a liquid composition including the substance and a solvent, and a removable micro-mold placed over the substrate and the liquid composition. To form the self assembly arrays of the substance, the solvent may be evaporated through at least one evaporation channel formed between the micro-mold and the substrate. The evaporation channel may be adjustable by subjecting the micro-mold to a positive pressure. | 2011-07-21 |
20110177979 | CARTRIDGE FOR CHEMICAL PROCESSING - A cartridge for chemical processing carries out chemical processing while moving a content by deformation based on an externally applied force, and includes a microarray chip housed in the cartridge for chemical processing; a member having a surface that faces a surface of the microarray chip; a supporting unit for supporting the member such that a width of a gap between the member and the microarray chip is variable by the externally applied force; and a limiting unit for restricting a variable range of the gap by the supporting unit such that the width of the entire gap between the surface of the member and the surface of the microarray chip does not become smaller than a predetermined width. | 2011-07-21 |
20110177980 | MICROFLUIDIC CHIP-BASED DNA COMPUTER - The present invention relates to computer science, molecular biology and microfluidics technique which provides a DNA molecular computer based on microfluidic chip. The objective is to provide a DNA molecular computer which uses the microfluidic chip as a operation platform, mainly including: using DNA molecules as operation media, using the microfluidic chip as the operation platform of a DNA molecular operator; using DNA molecules as storage media, using the microfluidic chip as the operation platform of a DNA molecular storage; using a electronic computer and a detector as the kernel of a controller; said microfluidic chip includes a DNA molecular computation region and a DNA molecular storage region. The microfluidic chip consists of digestion, ligation, PCR amplification and chip electrophoresis unit connected by microchannels in turn, and carries out the liquid control through micropumps and microvalves. | 2011-07-21 |
20110177981 | WELLBORE FLUIDS COMPRISING POLY(TRIMETHYLENE ETHER) GLYCOL POLYMERS - Wellbore fluids containing poly(trimethylene ether)glycols are provided. The wellbore fluids can provide enhanced functionality, improved cost effectiveness, and reduced environmental impact as compared to conventional wellbore fluids. | 2011-07-21 |
20110177982 | APPARATUS, COMPOSITIONS, AND METHODS OF BREAKING FRACTURING FLUIDS - Apparatus and compositions for reducing the viscosity of a gelled fluid is provided. In one embodiment, a viscosity reducing microbe is disposed in a capsule and added to the gelled fluid. The gelled fluid may include a thickening agent adapted to increase its viscosity. Upon release from the capsule, the microbe begins to digest the thickening agent in the gelled fluid and/or releases enzymes that that breakdown the thickening agent. | 2011-07-21 |
20110177983 | CATIONIC FLUORINATED POLYMER COMPOSITIONS AND METHODS FOR TREATING HYDROCARBON-BEARING FORMATIONS USING THE SAME - Fluorinated polymers having first divalent units independently represented by formula (I) or formula (II) and second divalent units containing quaternary ammonium groups. Compositions containing the fluorinated polymer and solvent, methods of treating hydrocarbon-bearing formations using these compositions, and articles treated with the fluorinated polymers are disclosed. A method of making a composition containing the fluorinated polymer is also disclosed. | 2011-07-21 |
20110177984 | Tagged Propping Agents and Related Methods - A proppant particle comprising a sintered proppant composition that comprises a non-radioactive, detectable tracer uniformly distributed throughout a ceramic composition, wherein the tracer is one or more tracer metal oxides and the tracer metals are selected from a group consisting of lanthanides, strontium, barium, gallium, germanium, tantalum, vanadium, and manganese. | 2011-07-21 |
20110177985 | Surfactants for Reduction of Water Blocks and/or Gas Condensates and Associated Methods - Improved methods of oil and/or gas production by reducing the occurrence of water blocks and/or gas condensates in the treated portion of the formation are provided. In one embodiment, the methods comprise: providing a treatment fluid comprising: an aqueous base fluid, a friction reducing agent, and a quaternary ammonium surfactant described by at least the following formula: | 2011-07-21 |
20110177986 | Method of Increasing pH of High-Density Brines - It has been discovered that carbonate powders and bicarbonate powders are useful to increase the pH and corrosion resistance of high-density brines, such as zinc bromide brines, without significantly reducing their densities. The carbonates and/or bicarbonates should be water-soluble and may be sodium, potassium, magnesium and/or ammonium carbonates and/or bicarbonates and the like. The carbonates and/or bicarbonates are easily added in powder or other finely divided solid form and are completely dissolved in the brine prior to pumping the brine into a subterranean formation. | 2011-07-21 |
20110177987 | METHOD FOR REDUCING FRICTION - The invention is directed to a method for reducing friction between at least two bodies. | 2011-07-21 |
20110177988 | Antiwear Composition and Method of Lubricating Driveline Device - The present invention relates to a method of driveline device by supplying to the driveline device a lubricating composition containing an oil of lubricating viscosity and an antiwear package, wherein the antiwear package includes: (a) derivatives of a carboxylic acid (typically a hydroxycarboxylic acid); and (b) a phosphorus compound. The invention further provides lubricating compositions containing an oil of lubricating viscosity and an antiwear package, wherein the antiwear package includes (a) derivatives of a carboxylic acid (typically a hydroxycarboxylic acid); and (b) an amine or metal salt of a phosphorus compound that is either (i) a hydroxy-substituted di-ester of (thio)phosphoric acid, or (ii) a phosphorylated hydroxy-substituted di- or tri-ester of (thio)phosphoric acid. | 2011-07-21 |
20110177989 | LUBRICATING COMPOSITIONS FOR TRANSMISSIONS - The present disclosure relates to lubricating compositions for transmissions, in particular for gear boxes, and to the use thereof for limiting the fuel consumption of motor vehicles. The compositions according to the disclosure are suitable for all types of vehicles, especially light vehicles, and are particularly suitable for hybrid engine vehicles. | 2011-07-21 |
20110177990 | Amylase Variants - The present invention relates to variants of a parent α-amylase, which parent α-amylase (i) has an amino acid sequence selected from the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No. 7, respectively; or (ii) displays at least 80% homology with one or more of these amino acid sequences; and/or displays immunological cross-reactivity with an antibody raised against an α-amylase having one of these amino acid sequences; and/or is encoded by a DNA sequence which hybridizes with the same probe as a DNA sequence encoding an α-amylase having one of these amino acid sequences; in which variant:
| 2011-07-21 |
20110177991 | Cleaner and polish formulation - A novel cleaner and polish formulation that is eco friendly, that is, it is formulated without alcohols, organic solvents and without normal cleaning and polishing components, for example, amine functional materials, that are undesirable with regard to the environment. | 2011-07-21 |
20110177992 | Aerosol Deodorizer - A cleaning solution includes an aqueous base, 0.1 wt % to 10 wt % of an organic acid, 0.1 wt % to 35 wt % of a surfactant, 0.1 wt % to 10 wt % of an organic ester derived from a carboxylic acid having at least 4 carbons, and 0.1 wt % to 11 wt % of an ethylene glycol ether. | 2011-07-21 |
20110177993 | Process of Preparing a Particle - A process for preparing a particle, the particle having: (i) cleaning active; (ii) structurant having a glass transition temperature; and (iii) optionally, plasticizer; wherein the process includes the step of: (a) contacting the plasticizer, the structurant, and the cleaning active to form a mixture, and forming a particle from the mixture; (b) optionally, removing at least part of the plasticizer from the mixture and/or particle of step (a); wherein the structurant undergoes a glass transformation during step (a) to create an amorphous structure which stabilizes the cleaning active. | 2011-07-21 |
20110177994 | FABRIC CARE COMPOSITION - A fabric enhancer composition comprising: (a) a cationic polymer; (b) less than about 20% silicone; and (c) a deposition aid; wherein the composition is essentially free of a coacervate. | 2011-07-21 |
20110177995 | FRAGRANCE MICROEMULSION COMPOSITIONS - The present invention relates to perfumed composition which comprises: a) from 1% to 25% by weight of a fragrance composition; b) from 1% to 10% by weight of at least one nonionic surfactant having at least two hydrophobic chains each containing from 4 to 20 carbon atoms; c) from 1% to 10% by weight of at least one anionic surfactant having at least two hydrophobic chains each containing from 4 to 20 carbon atoms; d) from 1% to 20% by weight of solvent which is a diol having from 4 to 12 carbon atoms, preferably from 4 to 8 carbon atoms, or a mixture of such diols; e) at least 50% by weight of water. | 2011-07-21 |
20110177996 | REGULATORY PROTEINS IN LUNG REPAIR AND TREATMENT OF LUNG DISEASE - The DNA-binding protein Sox17 has been found to play an important role in repair of pulmonary tissue after damage, disease, or injury. Nucleic acids encoding proteins involved in pulmonary repair, such as Sox17 and Spdef, can be used as a therapeutic composition for treating pulmonary disease. Methods of treatment of pulmonary injuries or pulmonary diseases are also disclosed, as are methods of identifying compounds effective in treating pulmonary injuries and diseases. | 2011-07-21 |
20110177997 | Cross-Beta Silk Genes - The present invention relates to silk proteins which can be used to produce silk with a cross-beta structure, as well as nucleic acids encoding such proteins. The present invention also relates to recombinant cells and/or organisms which synthesize silk proteins. Silk proteins of the invention can be used for a variety of purposes such as in the production of personal care products, plastics, textiles, and biomedical products. | 2011-07-21 |
20110177998 | BIOACTIVE PEPTIDES AND METHODS OF USING SAME - Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation. | 2011-07-21 |
20110177999 | Therapeutic Combinations Useful in Treating CFTR Related Diseases - The present invention relates to therapeutic combinations and kits useful in treating CFTR-related diseases, such as cystic fibrosis. | 2011-07-21 |
20110178000 | Apoptotically Active Peptides - Specific amino acid sequences and peptides and/or peptide mimetics deducted therefrom influencing apoptosis, and the use thereof for the production of pharmaceuticals as diagnostic tools are shown. | 2011-07-21 |
20110178001 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS - The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis. | 2011-07-21 |
20110178002 | High Affinity Ligands Bind to Clostridium Difficile Toxin A - Glycans are identified which have high affinity for | 2011-07-21 |
20110178003 | OPTIMIZED DENGUE VIRUS ENTRY INHIBITORY PEPTIDE (10AN) - The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds. | 2011-07-21 |
20110178004 | HEPATITIS B VIRUS PRE-S1 DERIVED SYNTHETIC POLYPEPTIDES AND USES THEREOF - The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies. | 2011-07-21 |
20110178005 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH OVERWEIGHT ANIMALS - The invention encompasses compositions and methods for treating disorders and diseases associated with overweight. The application also encompasses genes differentially expressed in animals and particularly to genes differentially expressed in overweight animals compared to lean animals. | 2011-07-21 |
20110178006 | METHOD FOR ADMINISTERING GLP-1 MOLECULES - The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating GLP-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention. | 2011-07-21 |
20110178007 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS - The present invention relates to compounds of the general formula: (I) wherein ring A, ring B, R | 2011-07-21 |
20110178008 | Compositions for Enhancing the Production of PPAR and/or PPAR-Associated Factors - The present inventors focused on certain nutritional compositions known to have activity of controlling blood glucose levels. These foods were administered to rats for long periods, and real-time PCR was used to analyze the expression of genes associated with lipid metabolism in the liver and adipose tissues. As a result, the present inventors found that the expression of the PPARα gene is enhanced by these foods, and that this is accompanied by suppressed expression of fatty acid synthase and enhanced expression of a group of PPARα target genes associated with fatty acid metabolism. The present inventors also confirmed the effect of these foods in enhancing the expression of PPARγ and adiponectin, and discovered that these foods have the activity of enhancing the production of PPAR and PPAR-associated factors. | 2011-07-21 |
20110178009 | Pheromones and the Luteinizing Hormone for Inducing Proliferation of Neural Stem Cells and Neurogenesis - The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions. | 2011-07-21 |
20110178010 | USE OF PEPTIDES FOR PROMOTING WOUND HEALING - The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications. | 2011-07-21 |
20110178011 | Polysaccharide/BMP complexes which are soluble at physiological pH - A complex of a polysaccharide and recombinant human BMP-2 and BMP-7, soluble at physiological pH, wherein the polysaccharide/BMP mass ratio is less than 15, the polysaccharide being selected from the group of polysaccharides having carboxyl functional groups, at least one of which is substituted with at least one hydrophobic radical. | 2011-07-21 |
20110178012 | USE OF HUMAN CHORIONIC GONADOTROPIN ORALLY FOR THE TREATMENT OF OVERWEIGHT (OBESITY) ASSOCIATED WITH HIGH BLOOD TENSION, NON-INSULIN-DEPENDANT DIABETES, HYPERCHOLESTEROLEMIA, DYSLIPIDEMIAS AND LIPODYSTROPHY. - Human chorionic gonadotropin administered by intramuscular route is traditionally used for the treatment of sterility and cryptorchidism. After numerous tests performed, a compound to be administered orally—sublingual—has been developed with such drug to treat patients suffering from overweight associated with high blood tension, non-insulin-dependant diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy. It was determined that hCG acts satisfactorily upon high blood tension, non-insulin-dependant diabetes, hypercholesterolemia, dyslipidemias and lipodystrophy. | 2011-07-21 |
20110178013 | NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF - The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal | 2011-07-21 |
20110178014 | PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS - Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment. | 2011-07-21 |
20110178015 | METHODS OF TREATMENT USING BIASED LIGANDS FOR RECEPTORS SUCH AS THE PTH RECEPTOR - Disclosed are compositions and methods for modulating the β-arrestin pathway selectively over the G protein pathway of a G protein couple receptor, such as parathyroid hormone receptor. | 2011-07-21 |
20110178016 | PULSE PARATHYROID HORMONE FOR TREATMENT OF THE HEMATOPOIETIC SYNDROME, STROMAL CELL LOSS, AND VASCULAR INJURY RESULTING FROM ACUTE EXPOSURE TO LETHAL RADIATION - Currently there is no treatment for hematopoietic syndrome following radiation exposure. Exposed persons are presently treated with blood transfusions, growth factors such as G-CSF to promote neutrophil recovery. Present methods are targeted towards the bone marrow microenvironment, aiding in repair and regeneration with a decrease in the severity or possibly, complete avoidance of morbidity and mortality associated with the hematopoietic syndrome. Methods are useful for treatment of mass casualties following a radiation disaster. | 2011-07-21 |
20110178017 | MODIFIED VASOACTIVE INTESTINAL PEPTIDES - The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP. | 2011-07-21 |
20110178018 | NOVEL SELENIUM-CONTAINING COMPOUNDS - A novel selenium-containing compound, a method of producing the selenium-containing compound, an analysis method using the selenium-containing compound, and use of the selenium-containing compound as an antioxidant, are disclosed. A novel selenium-containing compound shown by any of chemical formulas 1 to 4 is obtained by extracting a selenium-containing compound from a sample using an organic solvent or water, and purifying the selenium-containing compound. The novel selenium-containing compound may be used for a novel analysis method, or may be used as an antioxidant. | 2011-07-21 |
20110178019 | NEW PROTECTING COMPOSITIONS FOR RECOMBINANTLY PRODUCED FACTOR VIII - A histidine-free composition comprising:
| 2011-07-21 |
20110178020 | METHODS AND COMPOSITIONS FOR INHIBITION OF NEUTROPHIL EXOCYTOSIS - Isolated fusion polypeptides are provided that are comprised of a cell-penetrating polypeptide and a SNARE polypeptide aptamer. Further provided are methods for inhibiting neutrophil granule exocytosis that comprise contacting a neutrophil with a fusion polypeptide including a cell-penetrating polypeptide and a SNARE polypeptide aptamer such that the fusion polypeptide enters the neutrophil and inhibits neutrophil granule exocytosis. Also provided are methods for treating a neutrophil-mediated inflammatory disorder by inhibiting SNARE-associated exocytosis in neutrophils. | 2011-07-21 |
20110178021 | OPIORPHIN FOR USE AS A PSYCHOSTIMULANT AGENT - The present invention relates to peptides derived from human Basic Proline-rich Lacrimal Protein (BPLP), notably opiorphin, for use as psychostimulants. These peptides are useful in the treatment or prevention of diseases such as obsessive-compulsive disorder (OCD), narcolepsy, hypersomnia, vigilance drop, attention-deficit/hyperactivity disorder (ADHD), attention deficit and/or hyperactivity in adults and in children, depression, bipolar disease, dysthymic disorder and cyclothymic disorder. | 2011-07-21 |
20110178022 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION - The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, wherein an amino-terminal residue of the peptide is N-alkylated. Alternatively the compound of the invention comprises a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, where the first and second peptide or peptide analogue each comprise at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof. | 2011-07-21 |
20110178023 | Use Of SCO-Spondin Peptides For Inhibiting Or Preventing Neuronal Apoptosis Mediated By Cell Death Receptor Ligands - The invention relates to a polypeptide derived from the TSR (thrombospondin type 1 units) of SCO-Spondin for inhibiting or preventing the apoptosis mediated by the cell death receptor ligands, such as TRAIL or FasL. The polypeptide of the invention comprises a sequence -W-S-A1-C-S-A2-C-G- wherein A1 and A2 are amino acid sequences comprising 1 to 5 amino acids. More particularly, the invention relates to said polypeptide for inhibiting or preventing the apoptosis associated with a disease selected from the group consisting of neurodegenerative disorders, cerebral ischemia, neuronal traumas, neuronal inflammatory diseases, and viral neurodegenerations. | 2011-07-21 |
20110178024 | AMYLOID BETA-PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to polypeptides, compositions, and methods of use thereof for optimized treatment of diseases or disorders associated with amyloid beta protein (Aβ) accumulation in a subject. This invention also relates to polypeptides, compositions, and methods of use thereof for optimized immunization against diseases characterized by Aβ accumulation in a subject. This invention further relates to pharmaceutical formulations comprising these polypeptides and methods of use for administering to a subject an optimized Aβ peptide that elicits a beneficial T cell response; for example, a T cell response reducing Aβ accumulation in the brain of a subject, without causing an encephalitic response. | 2011-07-21 |
20110178025 | Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation - The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies. | 2011-07-21 |
20110178026 | RICIN-LIKE TOXINS FOR TREATMENT OF CANCER - The present invention provides a protein having chain of a ricin-like toxin, a B chain of a ricin-like toxin and a novel heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a specific protease such as those found in inflammatory cells and cancer cells. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying cells having a specific protease, such as cancer cells or inflammatory cells utilizing the nucleic acid molecules and proteins of the invention and pharmaceutical compositions for treating human inflammation and cancer. | 2011-07-21 |
20110178027 | Multi-LEU Peptides and Analogues Thereof as Selective PACE4 Inhibitors and Effective Antiproliferative Agents - Disclosed herein are PACE4 inhibitors, compositions comprising PACE4 inhibitors and their uses thereof for lowering PACE4 activity, reducing cell proliferation, reducing tumor growth, reducing metastasis formation, preventing and/or treating cancer. Also provided are methods for lowering PACE4 activity, reducing the proliferation of a cell, reducing tumor growth and/or treating and preventing cancer. Methods for screening PACE4 inhibitors and cell proliferation inhibitors are further provided. | 2011-07-21 |
20110178028 | METHOD FOR THE DETECTION OF PROVENTRICULAR DILATATION DISEASE AND KIT THEREOF - A ganglioside or a mixture of gangliosides, isolated from the peripheral and central nervous system of a bird, in particular a parrot, their use for the preparation of a medicament, methods for the diagnosis of Proventricular Dilatation Disease and diagnostic kits thereof, are disclosed. | 2011-07-21 |
20110178029 | Modified Human Apolipoprotein A-1 and Their Uses - Modified human apolipoprotein A-I polypeptides and uses thereof are provided. | 2011-07-21 |
20110178030 | METHODS OF TREATING INFLAMMATORY INTESTINAL DISEASE AND MANAGING SYMPTOMS THEREOF - Methods and products are disclosed for treating an inflammatory intestinal disease in a mammalian subject in need thereof, or preventing or reducing a symptom of inflammatory intestinal disease. These method include administering to the subject a therapeutically effective dose of (i) an isolated AvrA protein or polypeptide fragment thereof or (ii) a nucleic acid molecule encoding the isolated AvrA protein or polypeptide fragment. Preferred inflammatory intestinal diseases include Inflammatory Bowel Disease, Celiac Disease, and gastroenteritis. | 2011-07-21 |
20110178031 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID - The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid. | 2011-07-21 |
20110178032 | Monoglyceride of Acetoacetate and Derivatives for the Treatment of Neurological Disorders - This invention relates to methods of using the monoglyceride of acetoacetate and metabolic precursors for the treatment, prevention, inhibition or alleviation of neurological diseases associated with neuronal hypometabolism, such as Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia induced memory loss, age associated memory impairment (AAMI), Traumatic Brain Injury (TBI), Huntington's disease and many others. | 2011-07-21 |
20110178033 | GLUCOPYRANOSYL-SUBSTITUTED PHENYL DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE - Glucopyranosyl-substituted benzene derivatives of general formula I | 2011-07-21 |
20110178034 | PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS AND OTHER DISEASES WITH MONO- AND DISACCHARIDE-BASED COMPOUNDS - Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants. | 2011-07-21 |
20110178035 | METHOD FOR OBTAINING PURE MONOSIALOGANGLIOSIDE GM1 FOR MEDICAL USE - A process for preparing pure monosialoganglioside GM1 in the form of its sodium salt. There is provided a process for the isolation and purification of monosialoganglioside GM1 comprising (a) separation of GM1 from a lipidic mixture containing the monosialoganglioside GM1 as the main ganglioside component by ion exchange column-chromatography using an eluent comprising potassium or caesium ions, (b) recovery of the solute from the eluted solution, (c) diafiltration of an aqueous solution of the recovered solute, and (d) second diafiltration after the addition of 1 M NaCl, and recovering GM1. The purity level of GM1 obtained is higher than 99.0%. | 2011-07-21 |